Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy

E-ISSN： 1545-5017|62|6|1115-1115

ISSN： 1545-5009

Source： PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol.62, Iss.6, 2015-06, pp. : 1115-1115

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Reply to: Colon LB, Perissinotti A, Santarosa M, Marini BL. Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 6, 2015-06 ,pp. : 1116-1116

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical application of asparaginase activity levels following treatment with pegaspargase

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 6, 2015-06 ,pp. : 1102-1105

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 65, Iss. 3, 2018-03 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

D-Dimer Levels in Combination with Clinical Risk Factors Can Effectively Predict Subsequent Thromboembolic Events in Patients with Atrial Fibrillation during Oral Anticoagulant Therapy

Cardiology, Vol. 117, Iss. 1, 2010-09 ,pp. : 31-36

Karger

Access to resources Recommend Favorite

Long‐term monitoring during clofibrate therapy

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 11, Iss. 5, 1970-09 ,pp. : 689-697

John Wiley & Sons Inc

Access to resources Recommend Favorite